Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. clinical trials

A subsidiary of Sichuan Kelun Pharmaceutical Co.,Ltd.

The registry lists 55 studies whose lead sponsor is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. 33 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 55. List all 55 → · All Sichuan Kelun Pharmaceutical Co.,Ltd. studies →

• SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid TumorsRecruitingNCT06726369Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI FailureNot yet recruitingNCT07854509Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB118 Injection in Advanced Solid TumorsRecruitingNCT07586943Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With AsthmaRecruitingNCT07732023Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic CancerNot yet recruitingNCT07814066Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC ParticipantsRecruitingNCT07668154Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB565 for Injection in Advanced Solid TumorsRecruitingNCT07545265Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07622186Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT07329322Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Study of SKB103 in HER2-negative Breast CancerNot yet recruitingNCT07774624Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic CarcinomaRecruitingNCT07324629Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB264 in Combination With SKB118 for Non-Small Cell Lung CancerRecruitingNCT07697586Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB571 in Participants With Gastrointestinal TumorsRecruitingNCT07564466Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET AbnormalitiesRecruitingNCT07308106Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ AdenocarcinomaNot yet recruitingNCT07609667Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB103 for Injection in Advanced Solid TumorsRecruitingNCT07459998Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.RecruitingNCT05351788Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase II Study of SKB571 in Patients With Lung CancerRecruitingNCT07230405Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant TumorsRecruitingNCT07448922Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB518 in Patients With Advanced Solid TumorsRecruitingNCT06428331Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid TumorsRecruitingNCT06736327Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB315 in Patients With Advanced Solid TumorsRecruitingNCT05367635Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase 1 Study of SKB571 in Subjects With Advanced Solid TumorsRecruitingNCT06725381Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerRecruitingNCT06081959Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB445 for Injection in Solid TumorsRecruitingNCT06826040Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB518 in Patients With Lung CancerRecruitingNCT07019675Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB105 for Injection in Advanced Solid TumorsRecruitingNCT07380386Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis ParticipantsRecruitingNCT07488065Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB107 in Advanced Solid Tumors With Bone MetastasesRecruitingNCT07087197Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine TherapyRecruitingNCT07071337Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB500 Combinations in Patients With Small Cell Lung CancerRecruitingNCT07296809Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingNCT07299825Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06279364Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of A166 in Patients With Advanced Solid Malignant TumorsCompletedNCT05311397Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerCompletedNCT05445908Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB410 for Injection in Solid TumorsCompletedNCT05906537Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06670196Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OCActive, not recruitingNCT07341100Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of KL130008 in Adults With Severe Alopecia AreataTerminatedNCT05496426Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal CancerCompletedNCT03017807Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody TrialTerminatedNCT03426371Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB264 Monotherapy in Selected Subjects With Advanced Solid TumorsActive, not recruitingNCT05631262Phase 2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of KL590586 in Patients With Advanced Solid TumorsActive, not recruitingNCT05265091Phase 1/2

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06448312Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Study of Intratumoral KL340399 in Patients With Advanced Solid TumorsCompletedNCT05549804Phase 1

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05294172Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• A Phase III Study of SKB264 for EGFR Mutant NSCLC PatientsActive, not recruitingNCT05870319Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerActive, not recruitingNCT05347134Phase 3

  Sponsor listed in the registry: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.